argenex SE $ARGX Shares Bought by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC increased its position in shares of argenex SE (NASDAQ:ARGX) by 203.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,303 shares of the company’s stock after purchasing an additional 874 shares during the period. Valeo Financial Advisors LLC’s holdings in argenex were worth $718,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ARGX. Main Management ETF Advisors LLC raised its stake in shares of argenex by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock worth $808,000 after buying an additional 24 shares in the last quarter. IFP Advisors Inc boosted its stake in argenex by 4.2% during the second quarter. IFP Advisors Inc now owns 666 shares of the company’s stock valued at $367,000 after buying an additional 27 shares in the last quarter. Coldstream Capital Management Inc. grew its holdings in argenex by 7.6% during the second quarter. Coldstream Capital Management Inc. now owns 380 shares of the company’s stock worth $209,000 after acquiring an additional 27 shares during the period. Keudell Morrison Wealth Management raised its position in argenex by 5.5% in the second quarter. Keudell Morrison Wealth Management now owns 534 shares of the company’s stock worth $294,000 after acquiring an additional 28 shares in the last quarter. Finally, Central Pacific Bank Trust Division raised its position in argenex by 2.4% in the second quarter. Central Pacific Bank Trust Division now owns 1,278 shares of the company’s stock worth $704,000 after acquiring an additional 30 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Up 1.2%

ARGX opened at $862.05 on Thursday. The firm has a market capitalization of $53.08 billion, a P/E ratio of 37.01, a PEG ratio of 0.86 and a beta of 0.37. The stock has a fifty day moving average of $866.88 and a 200-day moving average of $723.04. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. On average, analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several recent research reports. Wedbush lifted their price objective on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Jefferies Financial Group set a $818.00 price target on argenex and gave the company a “buy” rating in a report on Tuesday, August 26th. Deutsche Bank Aktiengesellschaft lowered argenex from a “buy” rating to a “hold” rating in a research note on Thursday, September 11th. Finally, Wells Fargo & Company boosted their target price on argenex from $1,095.00 to $1,316.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $982.33.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.